CLASSIFICATION OF CURRENT ANTICANCER IMMUNOTHERAPIES

GALLUZI LORENZO ; VACCHELLI ERIKA; BRAVO SAN PEDRO JOSE MANUEL; BUQUE AITZIBER; SENOVILLA LAURA; BARACCO ELISA ELENA; BLOY NORMA; CASTOLDI FRANCESCA; ABASTADO JEAN PIERRE; AGOSTINIS PATRIZIA; APTE RON N; ARANDA FERNANDO; AYYOUB MAHA; BECKHOVE PHILIPP; BLAY JEAN YVES; BRACCI LAURA; CAIGNARD ANNE; CASTELLI CHIARA; CAVALLO FEDERICA; CELIS ESTABAN; CERUNDOLO VINCENZO; CLAYTON ALED; COLOMBO MARIO P; COUSSENS LISA; DHODAPKAR MADHAV; EGGERMONT ALEXANDER; FEARON DOUGLAS T; FRIDMAN WOLF H; FUCIKOVA JITKA; GABRILOVICH DMITRY; GALON JEROME; GARG ABHISHEK; GHIRINGHELLI FRANCOIS; GIACCONE GIUSEPPE; GILBOA ELI; GNJATIC SACHA; HOOS AXEL; HOSMALIN ANNE; JÄGER DIRK; KALINSKI PAWEL; KARRE KLAS; KEPP OLIVER; KIESSLING ROLF; KIRKWOOD JOHN M; KLEIN EVA; KNUTH ALEXANDER; LEWIS CLAIRE E; LIBLAU ROLAND; LOTZE MICHAEL T; LUGLI ENRICO; MACH JEAN PIERRE; MATTEI FABRIZIO; MAVILIO DOMENICO; MELERO IGNACIO; MELIEF CORNELIS J; MITTENDORF ELIZABETH; MORETTA LORENZO; ODUNSI ADEKUNKE; OKADA HIDEHO; PALUCKA ANNA KAROLINA; PETER MARCUS E; PIEN

ONCOTARGET

Impact Journals, LLC

Lugar: Depew, New York State, USA; Año: 2014 vol. 5 p. 12472 - 12508

1949-2553

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into "passive" and "active" based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.